Document is current
Any future updates will be listed below
-
Authors
Blanc, Frederic
Bouteloup, Vincent
Paquet, Claire
Chupin, Marie
Pasquier, Florence
Gabelle, Audrey
Ceccaldi, Mathieu
de Sousa, Paulo Loureiro
Krolak-Salmon, Pierre
David, Renaud
Fischer, Clara
Dartigues, Jean-François
Wallon, David
Moreaud, Olivier
Sauvée, Mathilde
Belin, Catherine
Harston, Sandrine
Botzung, Anne
Albasser, Timothée
Demuynck, Catherine
Namer, Izzie
Habert, Marie-Odile
Kremer, Stéphane
Bousiges, Olivier
Verny, Marc
Muller, Candice
Philippi, Nathalie
Chene, Geneviève
Cretin, Benjamin
Mangin, Jean-François
Dufouil, Carole
- License Information
-
More Information
Article History
Received: 2 February 2022
Accepted: 11 June 2022
First Online: 19 July 2022
Declarations
:
: This study was performed in accordance with the guidelines of the Declaration of Helsinki. The MEMENTO study protocol has been approved by the local ethics committee (“Comité de Protection des Personnes Sud-Ouest et Outre Mer III”; approval number 2010-A01394-35). All participants provided written informed consent.
: Not applicable.
: F.B. was the national coordinator for France for the Eisai Delphia (E2027) and Axovant Headway-DLB therapeutic trials; he is currently the national coordinator for France of the Roche Graduate therapeutic trial; he had received honoraria from Roche, Eisai, and Biogen for oral presentations. The other authors declare that they have no competing interests.
